Activated mesangial cells produce vascular permeability factor in early-stage mesangial proliferative glomerulonephritis.
Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a multifunctional cytokine involved in angiogenesis, inflammation, and wound healing. Although VPF/VEGF has been reported to be produced only by glomerular podocytes in glomeruli, it was found that it is produced by human cultured mesangial cells (MC). Therefore, immunohistochemical analysis (using indirect immunofluorescence and in situ hybridization) of VPF/VEGF in normal kidneys (n = 7) and biopsy specimens taken from 83 patients with renal diseases, including mesangial proliferative glomerulonephritis (PGN) (n = 58), was performed to examine whether VPF/VEGF is produced by MC in human PGN. In all of the healthy subjects and all of the patients except those with PGN (disease control subjects), VPF/VEGF protein and mRNA were detected mainly in podocytes. However, in some PGN patients, VPF/VEGF protein was demonstrated clearly in MC as well as in podocytes, as some of the VPF/VEGF was colocalized with alpha-smooth muscle actin, a marker of activated MC, and VPF/VEGF mRNA was expressed by MC and podocytes. Mesangial VPF/VEGF expression level increased significantly in PGN patients with early lesions (P < 0.01 versus healthy subjects or disease control subjects, P < 0.05 versus PGN with later lesions). The time between biopsy and disease onset was significantly shorter in PGN patients with than in those without mesangial VPF/VEGF expression (P < 0.01). These findings provide the first evidence that activated MC are a source of VPF/VEGF in human PGN, and indicate that mesangial VPF/VEGF expression is characteristic of early lesions of PGN. Because VPF/ VEGF plays a pivotal role in tissue repair, MC-produced VPF/VEGF may play pathophysiologic roles, including promoting recovery from glomerular injuries, in early-stage PGN.
Noguchi
K
K
Department of Pediatrics, Faculty of Health Science, Kobe University School of Medicine, Japan.
Yoshikawa
N
N
Ito-Kariya
S
S
Inoue
Y
Y
Hayashi
Y
Y
Ito
H
H
Nakamura
H
H
Iijima
K
K
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001707:Biopsy, Needle; D015153:Blotting, Western; D002648:Child; D002675:Child, Preschool; D016228:Endothelial Growth Factors / Q000032:analysis / Q000096:biosynthesis*; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D005920:Glomerular Mesangium / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D015432:Glomerulonephritis, Membranoproliferative / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D017403:In Situ Hybridization; D007223:Infant; D008222:Lymphokines / Q000032:analysis / Q000096:biosynthesis*; D008297:Male; D010865:Pilot Projects; D012016:Reference Values; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors